Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial
Rakesh Popat(University College London Hospitals NHS Foundation Trust), Neil Rabin(University College London), Claire Roddie(Cancer Institute (WIA)), Steve Schey(King's College London), Elizabeth H. Phillips(University of Manchester), Nicholas Counsell(University College London), Mickey Koh(St George's Hospital), Gordon Cook(University of Leeds), Laura Clifton‐Hadley(Cancer Research UK), Toyin Adedayo(Cancer Research UK), Matthew Streetly(King's College - North Carolina), Curly Morris(Belfast Health and Social Care Trust), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Dunnya De‐Silva(University of Liverpool), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Josephine Crowe(Royal United Hospital), Paul Smith(Cancer Research UK), Nivette Braganca(Cancer Research UK), Jamie Cavenagh(St Bartholomew's Hospital)
Cited by 5
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719